Regeneron (REGN, $652.99) awarded $450 million contract by the U.S. government, for developing coronavirus treatment
Regeneron shares climbed Tuesday, following news of the company being awarded a $450 million contract with the U.S. government, for developing coronavirus treatment.
The biotechnology company said that the contract will support it in boosting production of the REGN-COV2, conditional upon the success of clinical trials and Emergency Use Authorization or product approval from the Food and Drug Administration grants
REGN-COV2 is involved in two different clinical trials for both the treatment and prevention of the COVID-19.
Another biotech company Novavax also received a government contract, worth $1.6 billion from the federal government, to complete late-stage development of its NVX‑CoV2373 Covid-19 vaccine candidate, and to begin large-scale manufacturing and delivery of the drug by next year.
Tickeron's Comparison of Novavax, Inc. (NVAX) vs Regeneron Pharmaceuticals, Inc. (REGN) :
[NVAX & REGN] are closely correlated.
Both companies represent the Biotechnology industry
Market capitalization -- NVAX: $4.6B vs. REGN: $70.6B
Current volume relative to the 65-day Moving Average: NVAX: 37% vs. REGN: 68%
Brand notoriety: NVAX and REGN are both notable
Long term analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NVAX’s FA Score shows that 1 FA rating(s) are green while REGN’s FA Score has 3’s green FA rating(s).
- NVAX’s FA Score: 1 green, 4 red.
- REGN’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators.
NVAX’s TA Score shows that 3 TA rating(s) are bullish while REGN’s TA Score has 2’s bullish TA rating(s).
- NVAX’s TA Score: 3 bullish, 3 bearish.
- REGN’s TA Score: 2 bullish, 5 bearish.
REGN vs NVAX: Fundamental Ratings:
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVAX's Valuation (1) in the Biotechnology industry is significantly better than the same rating for REGN (85). This means that NVAX’s stock grew significantly faster than REGN’s over the last 12 months.
REGN's Profit vs Risk Rating (60) in the Biotechnology industry is somewhat better than the same rating for NVAX (100). This means that REGN’s stock grew somewhat faster than NVAX’s over the last 12 months.
REGN's SMR Rating (18) in the Biotechnology industry is significantly better than the same rating for NVAX (100). This means that REGN’s stock grew significantly faster than NVAX’s over the last 12 months.
REGN's Price Growth Rating (4) in the Biotechnology industry is in the same range as NVAX (34). This means that REGN’s stock grew similarly to NVAX’s over the last 12 months.
REGN's P/E Growth Rating (8) in the Biotechnology industry is significantly better than the same rating for NVAX (100). This means that REGN’s stock grew significantly faster than NVAX’s over the last 12 months.
REGN in upward trend: 10-day moving average moved above 50-day moving average on February 05, 2026
The 10-day moving average for REGN crossed bullishly above the 50-day moving average on February 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
REGN moved above its 50-day moving average on March 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in of 323 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 296 cases where REGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 64 cases where REGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on February 26, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on REGN as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for REGN turned negative on February 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
REGN broke above its upper Bollinger Band on February 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.643) is normal, around the industry mean (30.444). P/E Ratio (18.843) is within average values for comparable stocks, (40.910). Projected Growth (PEG Ratio) (1.671) is also within normal values, averaging (1.810). Dividend Yield (0.005) settles around the average of (0.042) among similar stocks. P/S Ratio (5.917) is also within normal values, averaging (314.598).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. REGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of medicines for the treatment of serious medical conditions
Industry Biotechnology
Advertisement